• Strata Critical Medical’s Nov. 3, 2026, third-quarter earnings call featured co-CEOs Will Heyburn and Melissa Tomkiel, alongside finance executive Mat Schneider.
• Management announced a $20 million share repurchase authorization, citing an attractive stock valuation.
• Revenue rose 50.3% to $74.1 million; adjusted EBITDA increased to $9.6 million from $4.2 million a year earlier.
• Full-year 2026 guidance remained unchanged: revenue of $285 million–$295 million, adjusted EBITDA of $33 million–$35 million.
• Management expects Clinical to lead 2027 growth, targeting high-teens organic adjusted EBITDA growth and more than 30% growth including acquisitions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Strata Critical Medical Inc. published the original content used to generate this news brief on November 03, 2026, and is solely responsible for the information contained therein.